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Background: Interferon-gamma (IFN-g) production by lymphocytes exposed to antigens
specific of Mycobacterium tuberculosis has been shown to correlate with antigen load and
disease activity.
Aim of study: To determine whether treatment of tuberculosis (TB) led to a decrease and/or
a reversion of results of a IFN-g release assay (T-SPOT.TB, Oxford Immunotec, UK) and thus if
T-SPOT.TB could be used to monitor response to treatment.
Methods: Qualitative and quantitative analysis (SFUs: spot-forming units) of T-SPOT.TB in
HIV-negative patients with TB, during initial 2 weeks of treatment (T0), at end of treatment
(TE) and 6 months later (TEþ 6).
Results: Mean SFU (SD) was 75 (58; nZ 62) at T0, 46 (55; nZ 55) at TE, and 33 (46; nZ 41) at
TE þ 6; positive rate was 98%, 93% and 98%, respectively. SFUs (paired samples, nZ 36)
decreased significantly between T0 and TE; 2 reversions occurred between T0 and TE (6%),
but none between TE and TEþ 6. Of 6 patients (17%) with an increase in SFUs between T0
and TE, 5 had a favourable outcome at TE and TEþ 6.
Conclusion: Decrease in SFUs under treatment suggests a relationship with antigen load;
however, persisting high SFUs were not predictive of unfavourable outcome and test reversion
was rare.
This trial was registered at www.clinicaltrials.gov (NCT00595907).
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Over the past 5 years, two assays (T-SPOT.TB, Oxford
Immunotec, UK and QuantiFERON-GOLD in tube, Cellestis,.
Figure 1 Study structure and number of samples analysed.
T0: blood samples within 2 weeks of beginning of treatment;
TE: blood samples at the end of treatment; TEþ 6: blood
samples 6 months after end of the treatment.
Interferon-gamma release assay results after treatment of tuberculosis 31Australia) measuring the production of interferon-gamma
(IFN-g) by peripheral blood lymphocytes exposed to anti-
gens highly specific of Mycobacterium tuberculosis (ESAT-6
and CFP-10), have become commercially available.1 In
patients with tuberculosis (TB), these tests, referred to as
IGRA (IFN-g release assays) have been shown to be at least
as sensitive as the tuberculin skin test (TST) for the
detection of infection by M. tuberculosis in immuno-
competent individuals, and much more specific. Their
major contribution is that they do not yield false positive
results in subjects with previous BCG vaccination, or
infection by most MOTT.2 IGRA have been recently included
in several national guidelines for the detection of latent
tuberculosis infection (LTBI) either as a replacement of the
TST, or as a complement in a ‘‘two-step procedure’’ (i.e.,
confirming positive TST results with an IGRA).3e5
Quantitative assessment of IFN-g production by sensi-
tized lymphocytes in response to ESAT-6 and/or CFP-10 has
been shown to correlate with disease activity although
these results are still debated. Monitoring of spot-forming
units (SFUs) in ELISPOT response to antigens specific of
M. tuberculosis (ESAT-6 and CFP-10) could thus theoretically
be useful for assessing response to treatment. This study
aimed therefore to determine, in immuno-competent
subjects treated for TB: (1) whether reversion of T-SPOT.TB
assay and/or a significant decrease in SFUs could be docu-
mented after treatment; (2) whether an increase in SFUs
was associated with an unfavorable clinical outcome; (3)
how results of the T-SPOT.TB evolved 6 months after
treatment completion.Patients and methods
Between October 1, 2004 and June 30, 2006, all subjects
either treated for culture-proven TB or having completed
their treatment within the past 6 months, and followed by
the Division of Pulmonary Diseases (Geneva University
Hospital) were prospectively invited to participate in this
study after informed consent. Exclusion criteria were age
under 18 years, history of prior active tuberculosis, and HIV
infection.
The study protocol was accepted by the ethics
committee on clinical research of Geneva University
Hospital. All subjects included provided written informed
consent. The trial was registered at www.clinicaltrials.gov
(NCT00595907).
Blood samples were taken within 2 weeks of initiation of
treatment (T0), at treatment completion (TE), and 6
months after treatment completion (TEþ 6) (Fig. 1).
Peripheral venous blood samples (8 ml) were processed
by our laboratory within 3 h of sampling for determination
of M. tuberculosis specific IFN-g secreting T cells using the
T-SPOT.TB IGRA (Oxford Immunotec, Oxford, UK) according
to the previously reported manufacturer’s recommenda-
tions.6 Tests were considered as indeterminate if SFUs in
the positive control were <20, or if SFUs in the negative
well were >10. Results were scored as positive if SFUs in
either ESAT-6 or CFP-10 wells were >6 spots above SFUs of
the negative control. SFU values are reported as [highest
SFU value of ESAT-6 or CFP-10 antigen SFU value of
negative control]. We also individually scored SFUs forESAT-6 and CFP-10 according to the same procedure ([SFU
value of either antigen SFU value of negative control]).
Statistical analysis
Data are reported as mean standard deviation (SD) unless
specified otherwise.
Paired observations (SFUs, T0eTE, TEeTEþ 6) were
compared by Wilcoxon signed rank test for results of
T-SPOT.TB, ESAT-6 and CFP-10 wells.
Unpaired observations were compared by ManneWhit-
ney rank-sum test. Level of significance was set at p< 0.05.
Results
Inclusion criteria were met by 89 HIV-negative patients (43
male, 46 female, aged 37 15 years, 90% foreign born). TB
was pulmonary in 70 subjects (79% of total, 86% smear posi-
tive), extra-thoracic in 34 (38% of total), and both in 15 (17%).
All patients had M. tuberculosis strains susceptible to major
tuberculostatic drugs, and were treated according to inter-
national ATS/CDC guidelines. None received corticosteroids
or any other immunosuppressive treatment. Compliance
to treatment was monitored either by DOT, or through
monthly urinary testing for isoniazid, and attendance to
clinical visits, and was optimal for all patients studied.
T-SPOT.TB was performed at T0 in 62 subjects, at TE in
55, and at TEþ 6 in 41 (Fig. 1). One T-SPOT.TB result was
indeterminate (1.1%).
Fig. 2 shows box plots for all subjects included; T-SPOT.TB
was positive in 62 of 63 samples at T0 (98%), 51 of 55 samples
at TE (93%), and 40 of 41 samples at TEþ 6 (98%). SFU counts
were significantly lower at TE than at T0 (p< 0.001), but
did not differ significantly between TE and TEþ 6.
Paired samples between T0 and TE were available for 36
subjects (1 indeterminate; Fig. 3). Average SFU counts
decreased from 101 47 to 55 60 (pZ 0.0002). SFU
counts increased in 6 cases, 5 of whom had an unremark-
able clinical resolution of their TB. One older patient with
disseminated TB relapsed shortly after a 12-month treat-
ment, and subsequently died of pneumonia. Two patients
reverted their T-SPOT.TB between T0 and TE.
Between TE and TEþ 6, paired samples (nZ 28) showed
a non-significant decrease in SFUs (67 60 vs. 54 54,
pZ 0.36), and no test reversion. Twelve subjects slightly
increased their SFU counts (Fig. 4); none relapsed during
study period.
Figure 4 Individual results for patients with paired samples
(nZ 28) between end of treatment (TE) and 6 months later
(TEþ 6); horizontal bars indicate mean values; p value given
for Wilcoxon signed rank tests. Dotted lines indicate subjects
(nZ 12) with an increase in SFU between TE and TEþ 6.
Figure 2 Box plot of spot-forming unit (SFU) counts of
subjects at the beginning of treatment for culture-proven
tuberculosis (T0; nZ 62), at the end of treatment (TE;
nZ 55), and 6 months after end of treatment (TEþ 6; nZ 41).
The box shows median value, 25th and 75th percentiles; bars
show 5th and 95th percentiles. p Values indicate results of
ManneWhitney rank-sum tests. Percentages in box plot indi-
cate rate of positive T-SPOT.TB according to manufacturer’s
recommendations.
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and TEþ 6; SFU counts decreased significantly between T0
and TE (111 60 vs. 60 57, pZ 0.01), and non-signifi-
cantly between TE and TEþ 6 (60 57 vs. 39 29,
pZ 0.10); among these patients, non-reverted.
SFU counts for both ESAT-6 or CFP-10 antigens decreased
significantly between T0 and TE, but not between TE and
TEþ 6 (data not shown).
Discussion
Data reported show that (1) the T-SPOT.TB was positive in
98% of subjects with TB during the first 2 weeks ofFigure 3 Individual results for patients with paired samples
(nZ 36) between beginning of treatment (T0) and end of
treatment (TE); horizontal bars indicate mean values; p value
given for Wilcoxon signed rank tests. Dotted lines indicate
subjects (nZ 6) with an increase in SFU between T0 and TE.treatment (which is in the upper range of previously
reported sensitivity of the T-SPOT.TB)2 and remained
positive in most patients 6 months after treatment
completion; (2) SFU counts decreased significantly between
T0 and TE, but test reversion was rare; 6 months after
treatment completion, SFU changes were non-significant,
and no further test reversion occurred; (3) a small number
of subjects increased their SFU counts between T0 and TE;
in most cases, however, this was not associated with an
adverse outcome.
Our results confirm previous observations suggesting
a relationship between bacterial load and number of g-IFN
producing antigen-specific effector T cells enumerated by
the T-SPOT.TB assay. The decrease in bacterial load
resulting from efficient antituberculous therapy would
explain why the number of ESAT-6 and CFP-10 specificFigure 5 Individual results for patients with paired samples
(nZ 20) available at beginning of treatment (T0), end of
treatment (TE) and 6 months later (TEþ 6); horizontal bars
indicate mean values; p value given for Wilcoxon signed rank
tests.
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ment of T-SPOT.TB results (SFU counts) could thus in theory
reflect bacterial burden and be used to monitor response to
TB treatment.7 Indeed, SFU counts have been reported as
significantly higher in subjects with TB than in subjects with
LTBI and no evidence of active disease.6 One case report
documented a progressive increase in ELISPOT response to
ESAT-6 and CFP-10 prior to diagnosis of TB, followed by
a decrease in SFUs under treatment.8 ELISPOT assays using
either ESAT-6 alone,9,10 or ESAT-6 and CFP-1011 have shown,
in adults with TB, a decrease in SFUs under treatment. A
slightly different time course has been reported in children
with TB, with an initial increase in response to ESAT-6
during the first month of treatment, followed by
a progressive decrease in response to both ESAT-6 and
CFP-10.12
One study documented a delayed drop in SFUs in late
responders to treatment in patients treated for TB: in these
patients, M. tuberculosis could still be cultured from either
sputum, blood or pleural fluid.9 The authors suggested that
a delayed drop in SFUs could be an indicator of adverse
prognosis and poor response to treatment. In the present
study, however, among 6 patients who increased their SFU
counts between T0 and TE (Fig. 3), 5 had a normal response
to treatment; none had persistent culture positive samples
after 2 months; one elderly patient relapsed early after
treatment completion and died subsequently of pneu-
monia. Among 12 patients who increased their SFU counts
during the 6 months following completion, none relapsed
(Fig. 4).
Reversion of IGRA results has been shown in two studies:
among 82 HIV-negative cases of TB successfully treated in
the Gambia, 44 (55%) were ELISPOT negative 12 months
after diagnosis.13 In Cape Town, 17 of 21 (81%) HIV-negative
patients who had successfully completed TB treatment
were IGRA negative.14 Our data do not confirm these high
reversion rates: 5.5% of patients reverted their T-SPOT.TB
between T0 and TE, and none during the following 6
months. Furthermore, patients sampled at TE and 6 months
later (Fig. 1) had, respectively, 93% and 98% of positive T-
SPOT.TB results.
Two limitations of this study must be mentioned: the
first is the relatively small number of cases, which is
related to the epidemiology of tuberculosis in Switzerland,
a low incidence country with an annual incidence of 8/
100,000 inhabitants; the second is the 25% rate of ‘‘lost to
follow-up’’ subjects between TE and TEþ 6: 90% of our
cases were foreign born, many of whom were either asylum
seekers or illegal migrants; although compliance was
excellent during treatment, this is a very mobile pop-
ulation for whom long term follow-up studies are difficult
to perform.
In summary, number of g-IFN producing antigen-specific
effector T cells decreased significantly in most TB cases
between diagnosis and treatment completion, thus con-
firming several reports showing a quantitative relationship
between disease activity (or antigen load) and IGRA results;
test reversion was, however, exceptional; furthermore,
most subjects with an increase in SFUs between T0 and TE
had an uneventful clinical improvement. These results
challenge the idea that IGRA can be used to monitor
treatment efficacy or risk of relapse.Conflict of interest statement
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